The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis

Journal of Hepatology

Volumn 62, Issue 2, 2015, Pages 311-316

  Londoño, Maria Carlota ^a   Perelló, Christie ^b   Cabezas, Joaquín ^c   Cañete, Nuria ^d   Lens, Sabela ^a   Mariño, Zoe ^a   Gambato, Martina ^a   Rodríguez, Raquel ^b   Menéndez, Susana ^c   Carrión, José A ^d   Crespo, Javier ^c   Calleja, José Luis ^b   Forns, Xavier ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cirrhosis; Infections; Triple therapy

Indexed keywords

ALBUMIN; BILIRUBIN; BOCEPREVIR; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; EAR INFECTION; ENTEROCOCCUS FAECALIS; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HERPESVIRIDAE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PNEUMOCOCCAL INFECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SKIN ABSCESS; STAPHYLOCOCCUS HOMINIS; STREPTOCOCCUS EQUINUS; STREPTOCOCCUS SANGUINIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS LOAD; BACTERIAL INFECTIONS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RISK FACTOR; SPAIN; VIROLOGY;

ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SPAIN;

EID: 84922253428     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.025     Document Type: Article

References (30)

1. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728.
2. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown Jr RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 2012; 57: 1752-1762.
3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
5. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
8. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441.
9. Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: E134.
10. Calleja J, Pascasio J, Antoran BR, Gea F, Barcena R, Larrubia J, et al. Safety and efficacy of triple therapy with peginterferon, ribavirin, and boceprevir within an early access program in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Liver Int 2014. http://dx.doi.org/10.1111/liv.12656, [Epub ahead of print].
11. Rutter K, Ferlitsch A, Maieron A, Stattermayer A, Graziadei I, Dulic M, et al. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced disease-predictive factors for sepsis. J Hepatol 2013; 58: S30.
12. Romero-Gomez M, Berenguer M, Molina E, Calleja JL. Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations. J Hepatol 2013; 59: 1323-1330.
13. WHO toxicity grading scale for determining the severy of adverse events; 2003 [cited 9/05/2014]. Available from: Http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary-06-2003%20final.pdf.
14. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown Jr RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 2013; 57: 1752-1762.
15. Acevedo J, Prado V, Fernandez J. Changing options for prevention and treatment of infections in cirrhosis. Curr Treat Options Gastroenterol 2014; 12: 256-267.
16. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol 2014; 60(6): 1310-1324.
17. Juarez-Navarro A, Vera-de-Leon L, Navarro JM, Chirino-Sprung R, Diaz- Hernandez M, Casillas-Davila L, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005; 27: 317-322.
18. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010; 52: 1225-1231.
19. Giorgini A, Capsoni F, Podda M, Lleo A, Battezzati PM, Ongari AM, et al. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. Ann N Y Acad Sci 2009; 1173: 847-857.
20. van der Berg CW, Tambourgi DV, Clark HW, Hoong SJ, Spiller OB, McGreal EP. Mechanism of neutrophil dysfunction: Neutrophil serine proteases cleave and inactivate the C5a receptor. J Immunol 2014; 192: 1787-1795.
21. Houston N, Stewart N, Smith DS, Bell SC, Champion AC, Reid DW. Sputum neutrophils in cystic fibrosis patients display a reduced respiratory burst. J Cyst Fibros 2013; 12: 352-362.
22. Gifford AM, Chalmers JD. The role of neutrophils in cystic fibrosis. Curr Opin Hematol 2014; 21: 16-22.
23. Luna-Gomes T, Filardy AA, Rocha JD, Decote-Ricardo D, LaRocque-de-Freitas IF, Morrot A, et al. Neutrophils increase or reduce parasite burden in Trypanosoma cruzi-infected macrophages, depending on host strain: Role of neutrophil elastase. PLoS One 2014; 9: E90582.
24. Prufer S, Weber M, Stein P, Bosmann M, Stassen M, Kreft A, et al. Oxidative burst and neutrophil elastase contribute to clearance of Aspergillus fumigatus pneumonia in mice. Immunobiology 2014; 219: 87-96.
25. Hadad N, Levy R, Schlaeffer F, Riesenberg K. Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition. Clin Vaccine Immunol 2007; 14: 1515-1521.
26. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT- 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973-1982.
27. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59(6): 2083-2091.
28. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial. Gastroenterology 2014; 146(7): 1669-1679.
29. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial. Gastroenterology 2014; 146: E436.
30. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013; 58: 1918-1929.